Rocket Pharmaceuticals, Inc.
$3.86
▼
-1.93%
2026-04-21 09:04:02
www.rocketpharma.com
NGM: RCKT
Explore Rocket Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$421.21 M
Current Price
$3.86
52W High / Low
$8.26 / $2.19
Stock P/E
—
Book Value
$2.56
Dividend Yield
—
ROCE
-76.11%
ROE
-60.27%
Face Value
—
EPS
$-2.01
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
202
Beta
0.57
Debt / Equity
8.97
Current Ratio
6.38
Quick Ratio
6.38
Forward P/E
-2.61
Price / Sales
—
Enterprise Value
$214.85 M
EV / EBITDA
-0.99
EV / Revenue
—
Rating
Buy
Target Price
$8.48
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Apellis Pharmaceuticals, Inc. | $40.94 | 233.76 | $5.23 B | — | 7.37% | 7.48% | $40.95 / $16.1 | $2.92 |
| 2. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 3. | ABVC BioPharma, Inc. | $1.3 | — | $33.58 M | — | -48% | -1.19% | $5.48 / $0.81 | $0.46 |
| 4. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 5. | NRx Pharmaceuticals, Inc. | $3.2 | — | $105.82 M | — | 103.85% | 146.18% | $3.84 / $1.62 | $-0.5 |
| 6. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
| 7. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -44.03 M | -52.42 M | -67.68 M | -64.39 M | -62.69 M | — |
| Net Profit | -42.54 M | -50.33 M | -68.92 M | -61.33 M | -60.33 M | — |
| EPS in Rs | -0.39 | -0.46 | -0.63 | -0.56 | -0.55 | -0.71 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -228.52 M | -273.2 M | -259.66 M | -223.84 M |
| Net Profit | -223.12 M | -258.75 M | -245.59 M | -221.86 M |
| EPS in Rs | -2.04 | -2.37 | -2.25 | -2.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 330.45 M | 527.7 M | 566.34 M | 551.81 M |
| Total Liabilities | 53.23 M | 64.47 M | 73.77 M | 62.12 M |
| Equity | 277.22 M | 463.23 M | 492.57 M | 489.69 M |
| Current Assets | 192.73 M | 378.18 M | 378.22 M | 364.06 M |
| Current Liabilities | 30.21 M | 40.68 M | 48.51 M | 39.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -190.01 M | -209.72 M | -194.92 M | -178.14 M |
| Investing CF | 103.77 M | 131.71 M | -98.07 M | -69.33 M |
| Financing CF | 0.15 M | 185.74 M | 208.4 M | 155.29 M |
| Free CF | -190.45 M | -215.59 M | -211.39 M | -186.76 M |
| Capex | -0.44 M | -5.86 M | -16.47 M | -8.62 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -5.35% | -10.7% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.